SCHEMBL6000224

SCHEMBL6000224

Cn1ccc2c(F)c(O)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 1/20 0.41
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
DHFR P00374 1/20 0.37
NQO2 P16083 1/20 0.36
HSD11B1 P28845 3/20 0.35
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
PRKCI P41743 1/20 0.33
ASH1L Q9NR48 1/20 0.33
AR P10275 1/20 0.33
MAOB P27338 1/20 0.32
ABCB11 O95342 1/20 0.31
P2RX7 Q99572 1/20 0.31
CYP2A6 P11509 1/20 0.31
TUBB4A P04350 1/20 0.31
TUBB P07437 1/20 0.31
TUBA3C P0DPH7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18527173 0.79 RHEB (0.47) RHEBKDM4EALDH1A1MAPTRXFP1
SCHEMBL18876105 0.78 RHEB (0.42) RHEBKDM4EALDH1A1MAPTRXFP1
SCHEMBL31705935 0.78 RHEB (0.42) RHEBKDM4EALDH1A1MAPTRXFP1
SCHEMBL5501732 0.78 HSD11B1 (0.39) RHEBKDM4EALDH1A1MAPTRXFP1
SCHEMBL31628177 0.76 RHEB (0.41) RHEBKDM4EALDH1A1MAPTRXFP1
SCHEMBL34472781 0.76 DHFR (0.44) RHEBKDM4EALDH1A1MAPTRXFP1
SCHEMBL23397300 0.76 HTR2C (0.37) ABCB11
SCHEMBL26569892 0.75 KDM4E (0.50) RHEBKDM4EALDH1A1MAPTRXFP1
SCHEMBL18052980 0.74 NOTUM (0.54) KDM4EALDH1A1ESR1ESR2ABCB11
SCHEMBL16065343 0.73 RHEB (0.39) RHEBKDM4EALDH1A1MAPTRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376478-B1 PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE NOVARTIS AG (CH) 2017-04-19 EP disclosed
US-20060058361-A1 Therapeutic diphenyl ether ligands PFIZER INC 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058361-A1 Therapeutic diphenyl ether ligands HTR2B, HTR2C, HTR3B RHEB 2914/4885KDM4E 649/4885ALDH1A1 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.